Selection of patients who will ultimately benefit from ECMO is crucial to the success of a service. Failure to select patents who will either recover or be suitable for further therapies will cause a lot of suffering, Patients will remain for weeks in intensive care with no prospect of recovery .Staff will lose morale by having to care for futile patients .Managers will question the high cost when assessed against outcome .